Itau Unibanco Holding S.A. Mirati Therapeutics, Inc. Transaction History

Itau Unibanco Holding S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $1,091 - $1,621	-26 Reduced 16.15%	135 $7,000
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $903 - $1,237	-25 Reduced 13.44%	161 $5,000
Q4 2022 Feb 09, 2023	SELL	$41.27 - $98.62 $1,361 - $3,254	-33 Reduced 15.07%	186 $8,000
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $156 - $354	4 Added 1.86%	219 $15,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $5,676 - $8,182	43 Added 25.0%	215 $32,000
Q3 2021 Nov 12, 2021	BUY	$132.13 - $177.45 $528 - $709	4 Added 2.38%	172 $30,000
Q2 2021 Aug 17, 2021	BUY	$144.0 - $179.73 $24,192 - $30,194	168 New	168 $27,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.